Inhibitory effects of prostaglandin D2 against the proliferation of human colon cancer cell lines and hepatic metastasis from colorectal cancer. 1998

T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
Second Department of Surgery, Fukushima Medical College, Japan.

The inhibitory action of prostaglandin D2 (PGD2) and its effect on the cell cycle were examined in cell lines SW480 and LS174T of human colon cancer. The growth of the cell lines were assessed 24 h and 48 h after the addition of 1.0 microgram/ml and 10.0 micrograms/ml PGD2. The growth of SW480 cells was inhibited 48 h, but not 24 h, after the addition of 1.0 microgram/ml, and 24 h and 48 h after the addition of 10.0 micrograms/ml, while that of LS174T was inhibited by both doses after 24 h and 48 h. S-Phase DNA synthesis in the SW480 cells was significantly blocked 24 h after the addition of 10.0 micrograms/ml PGD2. The cell cycle of LS174T cells was arrested at the G0 + G1 phase 24 h after the addition of 1.0 microgram/ml and 10.0 micrograms/ml PGD2. The correlation between hepatic metastasis and PGD2 concentration in human cancer tissue was examined. The mean value of PGD2 concentrations in the primary cancer tissue was significantly lower in the hepatic metastasis group than that in the group without hepatic metastasis. These findings suggest that measuring the PGD2 in cancer tissue may be useful for detecting and predicting the hepatic metastasis from human colorectal cancer.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015230 Prostaglandin D2 The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects. 11-Dehydroprostaglandin F2alpha,PGD2,11-Dehydroprostaglandin F2 alpha,11 Dehydroprostaglandin F2 alpha,11 Dehydroprostaglandin F2alpha,D2, Prostaglandin,F2 alpha, 11-Dehydroprostaglandin,F2alpha, 11-Dehydroprostaglandin,alpha, 11-Dehydroprostaglandin F2

Related Publications

T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
January 1995, Nihon Geka Gakkai zasshi,
T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
November 2018, Molecular and cellular biochemistry,
T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
January 2023, Clinics (Sao Paulo, Brazil),
T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
May 2006, Medicinal chemistry (Shariqah (United Arab Emirates)),
T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
October 2005, Journal of agricultural and food chemistry,
T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
January 2000, Oncology reports,
T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
March 1989, International journal of cancer,
T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
January 2017, Euroasian journal of hepato-gastroenterology,
T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
December 2019, Journal of gastrointestinal oncology,
T Yoshida, and S Ohki, and M Kanazawa, and H Mizunuma, and Y Kikuchi, and H Satoh, and Y Andoh, and A Tsuchiya, and R Abe
January 1996, Breast cancer research and treatment,
Copied contents to your clipboard!